Following is a message I sent today to Nader Pourh
Post# of 154867
(Total Views: 551)
Posted On: 04/07/2020 6:52:54 PM
Following is a message I sent today to Nader Pourhassan:
"Dr. Pourhassan:
The questions posed to you today by Charles Payne were not conducive to a good interview.
If faced with such unhelpful questions in another interview, I would respectfully suggest you pivot, and respond by providing the information you want to give.
So, for example, if you again get an opportunity to be interviewed on a national stage, or any television or radio interview for that matter, the first thing you should consider saying is something to this effect:
"Of the ____seriously ill COVID-19 patients who have been treated with Leronlimab, _____have extubated their ventilators within___days."
If you were to say this, and nothing else, you will have given a great interview.
Of course, you can also rattle off other bullet points such as:
1. In over 800 patients treated with Leronlimab, there has not been a single serious adverse event;
2. The FDA has approved leronlimab for two clinical trials; one for mild to moderately ill patients, and another for seriously ill patients;
3. The results of treating over___seriously ill COVID-19 patients have shown that the immune response is almost fully restored after seven days, and the cytokine storm has been reduced by as much as 70-90 percent in a matter of only a few days.
I hope this is helpful."
LM
"Dr. Pourhassan:
The questions posed to you today by Charles Payne were not conducive to a good interview.
If faced with such unhelpful questions in another interview, I would respectfully suggest you pivot, and respond by providing the information you want to give.
So, for example, if you again get an opportunity to be interviewed on a national stage, or any television or radio interview for that matter, the first thing you should consider saying is something to this effect:
"Of the ____seriously ill COVID-19 patients who have been treated with Leronlimab, _____have extubated their ventilators within___days."
If you were to say this, and nothing else, you will have given a great interview.
Of course, you can also rattle off other bullet points such as:
1. In over 800 patients treated with Leronlimab, there has not been a single serious adverse event;
2. The FDA has approved leronlimab for two clinical trials; one for mild to moderately ill patients, and another for seriously ill patients;
3. The results of treating over___seriously ill COVID-19 patients have shown that the immune response is almost fully restored after seven days, and the cytokine storm has been reduced by as much as 70-90 percent in a matter of only a few days.
I hope this is helpful."
LM
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]